Europe Digital Therapeutics (DTx) Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Europe Digital Therapeutics (DTx) Market Segmentation, By Product (Solutions/Software, Hardware Products, and Services), Application (Treatment, Preventive, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2032

Europe Digital Therapeutics (DTx) Market Size

• The Europe digital therapeutics (DTx) market size was valued at USD 862.86 million in 2024 and is expected to reach USD 4,639.40 million by 2032, at a CAGR of 23.4% during the forecast period
• The market growth is primarily driven by rising healthcare digitalization, increasing chronic disease burden, and growing demand for evidence-based, personalized therapy solutions across the region
• In addition, favorable regulatory frameworks, increased investment in healthtech innovation, and growing acceptance of digital therapeutics by healthcare professionals and patients as such as are reinforcing the role of DTx as a complementary or alternative therapeutic tool. These combined trends are accelerating market adoption, propelling the sector’s sustained expansion across Europe

Europe Digital Therapeutics (DTx) Market Analysis

• Digital therapeutics, delivering evidence-based therapeutic interventions via software to prevent, manage, or treat medical conditions, are becoming increasingly essential in Europe’s evolving healthcare landscape due to their scalability, cost-effectiveness, and ability to support chronic disease management and behavioral health
• The rising demand for DTx is driven by the growing prevalence of chronic conditions such as diabetes, cardiovascular diseases, and mental health disorders, coupled with increasing acceptance of digital health tools among both patients and healthcare providers
• Germany dominated the Europe digital therapeutics (DTx) market with the largest revenue share of 31.7% in 2024, driven by its Digital Health Applications (DiGA) initiative that enables reimbursement for prescribed DTx, a supportive regulatory environment, and strong integration of digital therapeutics into clinical care pathways
• Spain is expected to be the fastest growing country in the Europe digital therapeutics (DTx) market during the forecast period, supported by national digital health initiatives, increased healthcare digitization, and growing demand for remote, patient-centric therapeutic solutions
• Solutions/Software segment dominated the Europe digital therapeutics (DTx) market with a market share of 65.2% in 2024, driven by its ease of deployment, scalability, and widespread use in managing chronic and behavioral health conditions through mobile apps and cloud-based platforms

Report Scope and Europe Digital Therapeutics (DTx) Market Segmentation  

Europe Digital Therapeutics (DTx) Market Trends

“Widespread Integration with National Health Systems and Reimbursement Pathways”

• A key and accelerating trend in the Europe DTx market is the integration of digital therapeutics into public healthcare systems through structured regulatory and reimbursement frameworks. Countries such as Germany, the UK, and France are leading this transition by formalizing pathways for digital health tools to be prescribed and reimbursed similarly to traditional therapies

  • For instance, Germany’s Digital Health Applications (DiGA) framework allows certified digital therapeutics to be prescribed by physicians and reimbursed by statutory health insurers, fostering rapid adoption and innovation. France has also launched its PECAN program, aimed at integrating digital solutions for chronic disease care into its public system

• This shift is enabling DTx developers to gain clinical validation and commercial sustainability while increasing physician and patient trust. The frameworks typically require stringent clinical evidence, data security compliance, and real-world effectiveness, which pushes the market toward higher quality standards
• In addition, the ability to integrate with electronic health records (EHRs) and national digital health platforms further enhances the value proposition of DTx tools, offering seamless workflows for physicians and holistic care experiences for patients
• As governments across Europe increasingly recognize the potential of DTx to reduce healthcare costs and improve chronic disease outcomes, this trend is expected to expand into additional markets and therapeutic areas
• The growing policy support and institutional backing are not only helping scale adoption but also reshaping how therapies are delivered and reimbursed across Europe’s healthcare systems

Europe Digital Therapeutics (DTx) Market Dynamics

Driver

“Rising Chronic Disease Burden and Demand for Scalable Care Solutions”

• The escalating prevalence of chronic diseases such as diabetes, hypertension, cardiovascular conditions, and mental health disorders is a primary driver of the digital therapeutics market in Europe. These conditions require long-term, personalized management that traditional healthcare systems are often ill-equipped to provide at scale

  • For instance, in January 2024, Sidekick Health partnered with Pfizer to expand its DTx platform for inflammatory conditions across European markets, delivering targeted interventions through smartphones and wearables. Such collaborations highlight the growing confidence in DTx for real-world clinical application

• Digital therapeutics offer scalable, evidence-based solutions that empower patients with tools for self-management, behavior modification, and real-time feedback, helping reduce healthcare resource utilization
• The increasing pressure on healthcare systems to deliver value-based care is further pushing the adoption of DTx as an effective complement or alternative to conventional treatments
• Moreover, the flexibility of remote monitoring, personalization, and automated progress tracking make DTx particularly suited for the aging European population and those in underserved or rural regions

Restraint/Challenge

“Data Privacy Concerns and Regulatory Compliance Barriers”

• One of the most significant challenges in the Europe DTx market is ensuring compliance with complex regulatory and data privacy laws, particularly the General Data Protection Regulation (GDPR), which governs patient data usage, consent, and security.

  • For instance, while DiGA in Germany has accelerated market access, it requires strict adherence to data protection standards and proof of positive healthcare outcomes, which can be resource-intensive for emerging developers

• Patients and healthcare providers may also exhibit hesitancy in adopting DTx solutions due to concerns over data misuse, cybersecurity vulnerabilities, and the lack of long-term real-world efficacy data
• In addition, the fragmented regulatory landscape across European countries can make market entry and reimbursement navigation challenging for companies aiming to expand beyond a single national market
• Addressing these challenges through transparent data practices, advanced encryption, and strong evidence generation—combined with harmonization efforts by EU-level health agencies—will be crucial for long-term trust and scalability of DTx across Europe

Europe Digital Therapeutics (DTx) Market Scope

The market is segmented on the basis of product, application, end user, and distribution channel.

• By Product

On the basis of product, the Europe digital therapeutics (DTx) market is segmented into solutions/software, hardware products, and services. The solutions/software segment dominated the market with the largest revenue share of 65.2% in 2024, driven by its ease of deployment, cost-effectiveness, and scalability in delivering personalized interventions through apps and cloud platforms. Software-based DTx are widely used for managing chronic conditions such as diabetes and mental health through interactive, AI-driven therapy modules and real-time progress tracking.

The hardware products segment is anticipated to witness the fastest growth rate from 2025 to 2032, fueled by the increasing adoption of wearable devices and sensor-integrated tools that enhance patient monitoring and provide real-world health data to support therapeutic outcomes. These products are often used in tandem with software platforms to ensure continuous patient engagement and data-driven adjustments.

• By Application

On the basis of application, the Europe digital therapeutics (DTx) market is segmented into treatment, preventive, and others. The treatment segment held the largest revenue share of 58.3% in 2024, driven by the demand for DTx in managing chronic and behavioral health conditions such as diabetes, hypertension, and depression. These platforms deliver structured, evidence-based therapies that support medication adherence, behavioral change, and remote symptom tracking.

The preventive segment is expected to register the fastest CAGR during the forecast period, supported by increasing focus on lifestyle management, early intervention, and proactive health engagement strategies that reduce long-term healthcare costs and disease progression.

• By End User

On the basis of end user, the Europe digital therapeutics (DTx) market is segmented into hospitals, specialty clinics, home healthcare, and others. Hospitals dominated the market with a revenue share of 41.6% in 2024, as DTx solutions are increasingly being integrated into hospital workflows to support patient recovery, chronic disease management, and post-discharge monitoring. The institutional trust, availability of reimbursement pathways, and focus on value-based care make hospitals key adopters of digital therapeutics.

The home healthcare segment is projected to grow at the fastest rate during the forecast period, driven by rising demand for remote care, patient-centric models, and aging population trends. DTx solutions enable patients to manage their conditions from home, reducing hospital visits and supporting long-term care strategies.

• By Distribution Channel

On the basis of distribution channel, the Europe digital therapeutics (DTx) market is segmented into direct tender, retail sales, and others. Direct tender held the largest revenue share of 49.1% in 2024, driven by large-scale procurement by healthcare providers and institutions, particularly within national health systems and insurance-funded models in countries such as Germany and the UK. These structured purchases enable standardized deployment of DTx platforms across healthcare facilities.

Retail sales are expected to grow at the fastest pace over the forecast period, fueled by the increasing availability of DTx apps and platforms through app stores and direct-to-consumer models. The rise of consumer awareness and self-care trends is encouraging individuals to independently adopt digital therapies, especially for lifestyle and mental health conditions.

Europe Digital Therapeutics (DTx) Market Regional Analysis

• Germany dominated the Europe digital therapeutics (DTx) market with the largest revenue share of 31.7% in 2024, driven by its Digital Health Applications (DiGA) initiative that enables reimbursement for prescribed DTx, a supportive regulatory environment, and strong integration of digital therapeutics into clinical care pathways
• Consumers and healthcare providers in the region are increasingly adopting DTx solutions due to their proven clinical efficacy, ease of remote access, and ability to support long-term disease management, especially for chronic and mental health conditions
• This rising adoption is further supported by aging populations, expanding digital health infrastructure, and policy-level initiatives aimed at reducing healthcare costs and improving patient outcomes, positioning digital therapeutics as a key element in Europe’s future healthcare delivery models

Europe Digital Therapeutics (DTx) Market Insight

The Europe digital therapeutics (DTx) market is poised for significant growth during the forecast period, fueled by rising chronic disease prevalence, aging populations, and strong governmental support for digital health integration. Increasing healthcare costs and a push toward value-based care are encouraging the adoption of scalable, evidence-based digital therapeutic solutions. With greater regulatory clarity and reimbursement models emerging across multiple countries, digital therapeutics are gaining traction in clinical pathways for both treatment and prevention of chronic and behavioral health conditions.

Germany Digital Therapeutics (DTx) Market Insight

Germany digital therapeutics (DTx) captured the largest revenue share of 31.7% in the Europe DTx market in 2024, driven by its pioneering DiGA program, which allows prescribed DTx to be reimbursed under statutory health insurance. The country’s strong digital health infrastructure, combined with stringent clinical validation requirements, is fostering trust among healthcare providers and patients. Germany’s leadership in regulatory innovation is attracting global and domestic DTx developers, making it a central hub for digital health adoption in Europe.

U.K. Digital Therapeutics (DTx) Market Insight

The U.K. digital therapeutics (DTx) market is expected to grow at a robust CAGR during the forecast period, supported by the National Health Service’s (NHS) increasing use of digital tools for managing chronic conditions and mental health. The government’s commitment to digital-first care and widespread integration of telehealth and digital platforms positions the U.K. as a key adopter of DTx. Collaborations between public health bodies and private developers are also advancing the rollout of clinically validated digital therapies across diverse patient populations.

France Digital Therapeutics (DTx) Market Insight

France digital therapeutics (DTx) is emerging as a rapidly growing market for digital therapeutics, driven by the launch of national reimbursement pilots such as PECAN, aimed at integrating digital solutions into standard chronic care management. The country’s universal healthcare system and strong investment in digital transformation are creating favorable conditions for DTx deployment. Growing focus on patient-centered care and preventive health is further accelerating the adoption of digital therapeutic interventions, particularly in areas such as diabetes and cardiovascular health.

Spain Digital Therapeutics (DTx) Market Insight

Spain digital therapeutics (DTx) is expected to grow steadily due to rising investments in healthcare innovation, expansion of digital health infrastructure, and increasing acceptance of remote care models. As the healthcare system seeks cost-effective solutions for managing an aging population and chronic illnesses, DTx platforms are gaining interest. Local and regional health authorities are increasingly piloting digital solutions, especially for diabetes management, mental health support, and lifestyle modification.

Europe Digital Therapeutics (DTx) Market Share

The Europe Digital Therapeutics (DTx) industry is primarily led by well-established companies, including:

• Sidekick Health (Iceland)
• Kaia Health (Germany)
• HelloBetter (Germany)
• MySugr GmbH (Austria)
• Voluntis S.A. (France)
• Resilient Digital Health (France)
• MediBioSense Ltd. (U.K.)
• SilverCloud Health (U.K.)
• Happify Health (U.K.)
• Zanadio by aidhere GmbH (Germany)
• TicTrac Ltd. (U.K.)
• Cureety (France)
• Oviva AG (Switzerland)
• Doccla Ltd. (U.K.)
• Psious (Spain)
• S3 Connected Health (Ireland)
• Qolware GmbH (Germany)
• Amicomed (Italy)
• Sooma Oy (Finland)

What are the Recent Developments in Europe Digital Therapeutics (DTx) Market?

• In March 2024, Sidekick Health, an Iceland-based digital therapeutics company, expanded its partnership with Pfizer to launch DTx programs for inflammatory conditions across several European countries, including the U.K. and Germany. This collaboration focuses on delivering evidence-based digital therapies for chronic conditions, reinforcing Sidekick Health’s role in integrating DTx into mainstream healthcare and expanding access to personalized care solutions across Europe
• In February 2024, HelloBetter, a Germany-based DTx provider specializing in mental health, received permanent reimbursement status for several of its digital therapy programs under the DiGA framework. This marks a major milestone in Germany’s digital health strategy, demonstrating growing institutional trust in digital therapeutics and setting a precedent for long-term integration of DTx into national healthcare systems
• In January 2024, Kaia Health, headquartered in Germany, announced the expansion of its musculoskeletal (MSK) pain management platform in the U.K. and France, collaborating with local health providers to address rising demand for non-invasive, digital-first therapies. The initiative includes clinical studies and real-world evidence generation, supporting the company's broader goal of becoming a key MSK solution provider in the European healthcare market
• In December 2023, MediBioSense, a U.K.-based company specializing in connected health technologies, launched a DTx-enabled wearable platform targeting cardiac and respiratory patients. The device integrates with digital therapeutics software to deliver continuous monitoring and personalized therapy, addressing the growing need for remote, data-driven care across the U.K.'s National Health Service (NHS)
• In November 2023, Resilient Digital Health, a France-based startup, introduced a fully digital diabetes management program that combines behavioral interventions with real-time glucose tracking and AI-powered coaching. The program is being piloted in collaboration with public hospitals in Paris, aiming to reduce hospital readmissions and enhance patient engagement through digital-first care models

SKU-59881